Ponatinib with fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor chemotherapy for patients with blast-phase chronic myeloid leukaemia (MATCHPOINT): a single-arm, multicentre, phase 1/2 trial

doi:10.1016/S2352-3026(21)00370-7

Ponatinib with fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor chemotherapy for patients with blast-phase chronic myeloid leukaemia (MATCHPOINT): a single-arm, multicentre, phase 1/2 trial

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	e121-e132
Journal	The Lancet Haematology
Volume	9
Issue number	2
DOIs	https://doi.org/10.1016/S2352-3026(21)00370-7
Publication status	Published - Feb 2022
Externally published	Yes

ASJC Scopus Subject Areas

Hematology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S2352-3026(21)00370-7

Fingerprint

Dive into the research topics of 'Ponatinib with fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor chemotherapy for patients with blast-phase chronic myeloid leukaemia (MATCHPOINT): a single-arm, multicentre, phase 1/2 trial'. Together they form a unique fingerprint.

Cite this

@article{e1f132717b004f7491ab2757a756f1d3,

title = "Ponatinib with fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor chemotherapy for patients with blast-phase chronic myeloid leukaemia (MATCHPOINT): a single-arm, multicentre, phase 1/2 trial",

note = "Publisher Copyright: {\textcopyright} 2022 Elsevier Ltd",

year = "2022",

month = feb,

doi = "10.1016/S2352-3026(21)00370-7",

language = "English",

volume = "9",

pages = "e121--e132",

journal = "The Lancet Haematology",

issn = "2352-3026",

publisher = "Lancet Publishing Group",

number = "2",

}

TY - JOUR

T1 - Ponatinib with fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor chemotherapy for patients with blast-phase chronic myeloid leukaemia (MATCHPOINT)

T2 - a single-arm, multicentre, phase 1/2 trial

PY - 2022/2

Y1 - 2022/2

UR - http://www.scopus.com/inward/record.url?scp=85123730194&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85123730194&partnerID=8YFLogxK

U2 - 10.1016/S2352-3026(21)00370-7

DO - 10.1016/S2352-3026(21)00370-7

M3 - Article

C2 - 34906334

AN - SCOPUS:85123730194

SN - 2352-3026

VL - 9

SP - e121-e132

JO - The Lancet Haematology

JF - The Lancet Haematology

IS - 2

ER -

Ponatinib with fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor chemotherapy for patients with blast-phase chronic myeloid leukaemia (MATCHPOINT): a single-arm, multicentre, phase 1/2 trial

ASJC Scopus Subject Areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this